FDA-Approved Therapy Delays Type 1 Diabetes Onset by About Two Years

A newly FDA-approved injectable drug called teplizumab may slow the progression to symptomatic Type 1 diabetes for people in early stages of the disease. Here's what the approval means for patients and families.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

Teplizumab is an injectable therapy given over 14 days that works by modifying T cells to reduce their attack on insulin-producing beta cells.
The therapy is approved for people ages 8 and older who have Stage 2 Type 1 diabetes—meaning they have Type 1 diabetes antibodies but no symptoms yet.
In studies, teplizumab delayed the onset of symptomatic Type 1 diabetes by an average of about two years.
This is a delay therapy, not a cure; it may give patients and families more time before managing symptomatic diabetes.
Researchers are continuing clinical trials in children and adolescents ages 8–17 diagnosed within six weeks of initial symptoms.

What Is Teplizumab?

Teplizumab is an injectable drug administered over 14 days that has recently received FDA approval. It works by modifying T cells—the immune cells that, in Type 1 diabetes, mistakenly attack the beta cells in the pancreas that produce insulin.

By interrupting this harmful immune process, teplizumab may slow the progression of Type 1 diabetes before symptoms appear.

Who Can Receive This Therapy?

Teplizumab is approved for people ages 8 and older who are in Stage 2 Type 1 diabetes. This stage is characterized by the presence of Type 1 diabetes antibodies in the bloodstream and irregular blood sugar levels, but without the typical symptoms of diabetes such as excessive thirst, mood changes, or frequent urination.

If you or a family member may be eligible, discuss this therapy with your healthcare provider, who can assess individual circumstances and medical history.

What Does the Research Show?

In clinical studies, teplizumab delayed the onset of symptomatic Type 1 diabetes by an average of approximately two years in eligible patients. Researchers are continuing to test the therapy in children and adolescents ages 8–17 who have been recently diagnosed.

This delay may provide patients and families with additional time before managing symptomatic Type 1 diabetes, though more research is ongoing to understand the therapy's long-term effects and potential benefits in different populations.

What This Means Going Forward

The FDA approval of teplizumab represents an important development for people identified early in Type 1 diabetes progression. It is the first therapy of its kind to receive approval for delaying Type 1 diabetes onset in this population.

If you have concerns about your risk for Type 1 diabetes or have been diagnosed in an early stage, talk with your doctor about whether screening or discussing teplizumab may be appropriate for your situation.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.